The Healthy Microbiome—What Is the Definition of a Healthy Gut Microbiome?

doi:10.1053/j.gastro.2020.09.057

Gastroenterology

Volume 160, Issue 2, January 2021, Pages 483-494

https://doi.org/10.1053/j.gastro.2020.09.057 Get rights and content

Use of microbiome-based biomarkers in diagnosis, prognosis, risk profiling, and precision therapy requires definition of a healthy microbiome in different populations. To determine features of the intestinal microbiota associated with health, however, we need improved microbiome profiling technologies, with strain-level resolution. We must also learn more about how the microbiome varies among apparently healthy people, how it changes with age, and the effects of diet, medications, ethnicity, geography, and lifestyle. Furthermore, many intestinal microbes, including viruses, phage, fungi, and archaea, have not been characterized, and little is known about their contributions to health and disease.Whether a healthy microbiome can be defined is an important and seemingly simple question, but with a complex answer in continual need of refinement.

Graphical abstract

Section snippets

Dear Doctor

Dear Dr…I have discovered what none of my previous doctors could tell me about my body. I paid for an expensive microbiome test at a private laboratory and found that my microbiome is abnormal and damaging my health. I’m convinced this is causing of all of the medical problems I’ve suffered from since childhood, which the doctors could not diagnose. I urgently need fecal microbial transplantation (FMT) to get well. My friend will be the donor. Please arrange for me to have the FMT.

Loaded with

What’s in a Word?

In one of the great lessons on communication, Humpty Dumpty said to Alice: "When I use a word…it means just what I choose it to mean—neither more nor less."¹⁴ Mister Dumpty’s point is that words don’t mean the same thing to everyone; they can be loaded with implications and change meaning over time. Language and logic are inseparable, and misuse of words in microbiome science has been addressed elsewhere.¹⁵ However, few words are as ambiguous or as fickle as health.

There is no universally

Classifying Microbiomes

The concept of a “core” microbiome, originally considered as a common set of microbes required by the host for maintenance of health, has given way to pursuit of core functions for the microbiome, but these vary with context, and multiple definitions of what constitutes a core microbiome have emerged with no consensus (reviewed in Risely⁴⁴). Similarly, attempts to define distinct compositional “enterotypes” within the population have been both insightful and controversial.⁴⁵

Concepts of a

Functional Redundancy

Because different bacteria often share a capacity for similar metabolic functions, multifunctional redundancy is an important characteristic of the gut microbiome. Thus, despite extreme interindividual compositional diversity and intraindividual temporal variability of the gut microbiome, metabolic function is much less diverse and is highly conserved. This suggests that a functional definition (metabolomic and metaproteomic) may be superior to taxonomy in distinguishing normal from an abnormal

Lessons From Outliers

Exceptional data that fall outside conventional boundaries are an opportunity to challenge and revise established concepts in biology. In particular, outliers can refine what constitutes a healthy microbiome. For example, the Irish Travellers are an ethnically distinct subpopulation accounting for almost 1% of the population of Ireland, a socioeconomically developed country, but have a strikingly distinct microbiome. In a study that controlled for genetic and geographic factors, the Irish

Strains Matter

We have known for some time, through the application of relatively unsophisticated techniques such as molecular fingerprinting, that some sub-dominant gut commensals like Lactobacillus reuteri display strain-specific associations with major host lineages.⁵⁴ These associations correlate with significant differences in gene content. As microbiome research has matured in the past 5 years, it has become apparent that strain-level heterogeneity of many gut species is important. This could not be

The Changing Nature of the Microbiome and Its Clinical Implications

The elements that contribute to most NCCDs are genes, environment, and time, and the microbiome engages with each element of this triad. One of the most studied NCCDs from a microbiome perspective has been obesity, and yet no single microbial biomarker has been identified. This illustrates both the complexity of the relationships and the challenges involved if analysis is limited to compositional rather than functional analysis.

Although the human microbiome has evolved over millennia and

Beyond Bacteria

Another challenge for establishing the clinical importance of interindividual differences in the gut microbiome is the fact that some parts of the total microbiome are poorly characterized. The term “dark matter” has been invoked to describe the communities of bacteriophage and uncultured bacteria in the human gut,⁷¹^,⁷² the biological significance of which is largely unknown. Interactions between the gut mycobiome and the host are also poorly understood.⁷³ The same uncertainty extends to

Future Directions

Predictions about the future are generally hazardous and unwise, prophecy even more so, but these differ from projection, which is easier because it is an extension of current trends. For example, it is customary for reviews of microbiome medicine and science to call for the focus to shift from composition to function, from correlation to causation, from observation to mechanism, and from cross-sectional to longitudinal studies. Equally self-evident is the value of larger cohorts of study

Acknowledgments

Author contributions: All three authors are responsible for writing, review & editing the manuscript.

References (81)

D. Zeevi et al.
personalized nutrition by prediction of glycemic responses
Cell
(2015)
M.X. Byndloss et al.
Healthy hosts rule within: ecological forces shaping the gut microbiota
Mucosal Immunol
(2018)
M.I. McBurney et al.
Establishing what constitutes a healthy human gut microbiome: state of the science, regulatory considerations, and future directions
J Nutr
(2019)
E. Pasolli et al.
Extensive unexplored human microbiome diversity revealed by over 150,000 genomes from metagenomes spanning age, geography, and lifestyle
Cell
(2019)
K. Barnett et al.
Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study
Lancet
(2012)
C.D. Robinson et al.
Scales of persistence: transmission and the microbiome
Curr Opin Microbiol
(2019)
J. Walter et al.
Establishing or exaggerating causality for the gut microbiome: lessons from human microbiota-associated rodents
Cell
(2020)
F. De Filippis et al.
Distinct genetic and functional traits of human intestinal Prevotella copri strains are associated with different habitual diets
Cell Host Microbe
(2019)
A. Tett et al.
The Prevotella copri complex comprises four distinct clades underrepresented in westernized populations
Cell Host Microbe
(2019)
C.A. Thaiss et al.
Transkingdom control of microbiota diurnal oscillations promotes metabolic homeostasis
Cell
(2014)

K. Frazier et al.

Intersection of the gut microbiome and circadian rhythms in metabolism

Trends Endocrinol Metab

(2020)

J.L. Kaczmarek et al.

Time of day and eating behaviors are associated with the composition and function of the human gastrointestinal microbiota

Am J Clin Nutr

(2017)

S.J. Ott et al.

Efficacy of sterile fecal filtrate transfer for treating patients with Clostridium difficile infection

Gastroenterology

(2017)

M. Khan Mirzaei et al.

Bacteriophages isolated from stunted children can regulate gut bacterial communities in an age-specific manner

Cell Host Microbe

(2020)

N. Lane

The unseen world: reflections on Leeuwenhoek (1677) ‘Concerning little animals

Phil Trans R Soc B

(2015)

N. Kodaman et al.

Human and Helicobacter pylori coevolution shapes the risk of gastric disease

Proc Natl Acad Sci U S A

(2014)

S. Backert et al.

The role of CagA in the gastric biology of Helicobacter pylori

Cancer Res

(2016)

M.J. Blaser

Disappearing microbiota: Helicobacter pylori protection against esophageal adenocarcinoma

Cancer Prev Res (Phila)

(2008)

B. Flemer et al.

The oral microbiota in colorectal cancer is distinctive and predictive

Gut

(2018)

J. Wirbel et al.

Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer

Nat Med

(2019)

C.L. Murphy et al.

The gut microbiota in causation, detection, and treatment of cancer

Am J Gastroenterol

(2019)

M. O'Connell Motherway et al.

A Bifidobacterial pilus-associated protein promotes colonic epithelial proliferation

Mol Microbiol

(2019)

F. Shanahan

Gut microbes: from bugs to drugs

Am J Gastroenterol

(2010)

M.J. Claesson et al.

A clinician's guide to microbiome analysis

Nat Rev Gastroenterol Hepatol

(2017)

P.I. Costea et al.

Towards standards for human fecal sample processing in metagenomic studies

Nat Biotechnol

(2017)

T. Dalrymple

The meaning of health scares

(1998)

L. Carroll et al.

Through the looking-glass. chapter 6

(1934)

F. Shanahan et al.

Language, numeracy and logic in microbiome science

Nat Rev Gastroenterol Hepatol

(2019)

F. Backhed et al.

Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications

Cell Host Microbe

(2012)

J. Lloyd-Price et al.

The healthy human microbiome

Genome Med

(2016)

M. Eisenstein

The hunt for a healthy microbiome

Nature

(2020)

A.K. Manrai et al.

In the era of precision medicine and big data, who is normal?

JAMA

(2018)

D. McDonald et al.

American gut: an open platform for citizen science microbiome research

mSystems

(2018)

Rothschild D, Leviatan S, Hanemann A, et al. An atlas of robust microbiome associations with phenotypic traits based on...

G. Falony et al.

Population-level analysis of gut microbiome variation

Science

(2016)

A. Zhernakova et al.

Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity

Science

(2016)

A.G. Clooney et al.

Ranking microbiome variance in inflammatory bowel disease: a large longitudinal intercontinental study [published online ahead of print June 14, 2020]

Gut

(2020)

D. Rothschild et al.

Environment dominates over host genetics in shaping human gut microbiota

Nature

(2018)

M. Deschasaux et al.

Depicting the composition of gut microbiota in a population with varied ethnic origins but shared geography

Nat Med

(2018)

Y. He et al.

Regional variation limits applications of healthy gut microbiome reference ranges and disease models

Nat Med

(2018)

Cited by (172)

Combined dilute alkali and milling process enhances the functionality and gut microbiota fermentability of insoluble corn fiber
2024, Food Chemistry
In this study, we developed a process combining dilute alkali (NaOH or NaHCO₃) and physical (disk milling and/or ball milling) treatments to improve the functionality and fermentability of corn fiber. The results showed that combining chemical with physical processes greatly improved the functionality and fermentability of corn fiber. Corn fiber treated with NaOH followed by disk milling (NaOH-DM-CF) had the highest water retention (19.5 g/g), water swelling (38.8 mL/g), and oil holding (15.5 g/g) capacities. Moreover, NaOH-DM-CF produced the largest amount (42.9 mM) of short-chain fatty acid (SCFA) during the 24-hr in vitro fermentation using porcine fecal inoculum. In addition, in vitro fermentation of NaOH-DM-CF led to a targeted microbial shifting to Prevotella (genus level), aligning with a higher fraction of propionic acid. The outstanding functionality and fermentability of NaOH-DM-CF were attributed to its thin and loose structure, decreased ester linkages and acetyl groups, and enriched structural carbohydrate exposure.
Effect of tebipenem pivoxil hydrobromide on the normal gut microbiota of a healthy adult population in Sweden: a randomised controlled trial
2024, The Lancet Microbe
Antimicrobials cause perturbations in the composition and diversity of the host microbiome. We aimed to compare gut microbiome perturbations caused by oral tebipenem pivoxil hydrobromide (a novel carbapenem) and by amoxicillin–clavulanic acid (an orally administered β-lactam–β-lactam inhibitor combination widely used in clinical practice).
We did a phase 1, single-centre, randomised, parallel-group, active-control trial to evaluate the effect of tebipenem pivoxil hydrobromide on the human gut microbiota. Healthy participants aged 18 years or older with no documented illnesses during recruitment were enrolled at Karolinska University Hospital (Stockholm, Sweden). Study participants were stratified by sex and block-randomised in a 1:1 ratio to treatment with either tebipenem pivoxil hydrobromide (600 mg orally every 8 h) or amoxicillin–clavulanic acid (500 mg amoxicillin and 125 mg clavulanic acid orally every 8 h). The study included 10 days of treatment (days 1–10) and four follow-up visits (days 14, 21, 90, and 180). The trial was open-label for clinical investigators and patients, but masked for microbiology investigators. Faecal samples were collected at all visits. Sequencing of 16S rDNA was used to measure the diversity metrics, and quantitative culture to quantify selected taxa. The primary outcomes were changes in the α and β diversity and log count of colony-forming units for selected taxa between samples compared with baseline (day 1), and whether any changes reverted during the follow-up period. The analyses were done in the intention-to-treat population. This study was registered with ClinicalTrials.gov (NCT04376554).
The study was conducted between Jan 23, 2020, and April 6, 2021. 49 volunteers were screened for eligibility, among whom 30 evaluable participants (14 men and 16 women) were assigned: 15 (50%) to the tebipenem pivoxil hydrobromide group and 15 (50%) to the amoxicillin–clavulanic acid group. Baseline characteristics were similar between groups. Complete follow-up was available for all participants, and all participants except one completed treatment as assigned. The diversity metrics showed significant changes from baseline during the treatment period. Significant decreases in richness were observed on days 4–10 (p≤0·0011) in the amoxicillin–clavulanic acid group and on days 4–14 (p≤0·0019) in the tebipenem pivoxil hydrobromide group. Similarly, evenness was significantly decreased during treatment in the amoxicillin–clavulanic acid group (day 4, p=0·030) and the tebipenem pivoxil hydrobromide group (days 4–10, p<0·0001) compared with baseline. Quantitative cultures showed significant decreases in Enterobacterales (days 4–7, p≤0·0030), Enterococcus spp (days 4–14, p=0·025 to p<0·0001), Bifidobacterium spp (days 2–4, p≤0·026), and Bacteroides spp (days 4–10, p≤0·030) in the tebipenem pivoxil hydrobromide group. Similarly, in amoxicillin–clavulanic acid recipients, significant changes were observed in Enterobacterales (days 4–10, p≤0·048), Bifidobacterium spp (days 2–4, p≤0·013), and Lactobacillus spp (days 2–4, p≤0·020). Samples from the follow-up period were not significantly different from those at baseline in β diversity analysis (PERMANOVA, p>0·99). By the end of the study, no significant change was observed compared with baseline in either group. There were no deaths or severe adverse events.
The impact of tebipenem pivoxil hydrobromide on the gut microbiome was similar to that of amoxicillin–clavulanic acid. The safety of antibiotic use with regard to the microbiome should be given attention, as dysbiosis is associated with health and disease.
Spero Therapeutics.
The influence and therapeutic effect of microbiota in systemic lupus erythematosus
2024, Microbiological Research
Systemic erythematosus lupus (SLE) is an autoimmune disease involving multiple organs that poses a serious risk to the health and life of patients. A growing number of studies have shown that commensals from different parts of the body and exogenous pathogens are involved in SLE progression, causing barrier disruption and immune dysregulation through multiple mechanisms. However, they sometimes alleviate the symptoms of SLE. Many factors, such as genetic susceptibility, metabolism, impaired barriers, food, and sex hormones, are involved in SLE, and the microbiota drives the development of SLE either by depending on or interacting with these factors. Among these, the crosstalk between genetic susceptibility, metabolism, and microbiota is a hot topic of research and is expected to lay the groundwork for the amelioration of the mechanism, diagnosis, and treatment of SLE. Furthermore, the microbiota has great potential for the treatment of SLE. Ideally, personalised therapeutic approaches should be developed in combination with more specific diagnostic methods. Herein, we provide a comprehensive overview of the role and mechanism of microbiota in lupus of the intestine, oral cavity, skin, and kidney, as well as the therapeutic potential of the microbiota.
Dynamic nature of viral and bacterial communities in human faeces
2024, iScience
Bacteriophages are a major component of the gut microbiome and are believed to play a role in establishment and stabilization of microbial communities by influencing taxonomic and functional diversity. We show that the activity of lytic and temperate phages can also significantly affect bacterial community structure in a model of extended colonic retention. Intact fresh human feces were incubated anaerobically at 37°C without homogenization and subjected to metagenomic sequencing. We observed subject-specific blooms and collapses of selected bacteriophage and bacterial populations within some individuals. Most notable were striking collapses of Prevotella populations accompanied by increases in specific bacteriophages. In a number of cases, we even observed a shift from one bacterial “enterotype” to another within 48 h. These results confirm that intact feces represents a highly dynamic ecological system and suggests that colonic retention time could have a profound effect on microbiome composition, including a significant impact by bacteriophages.
Clinical and Preclinical Evidence for Gut Microbiome Mechanisms in Substance Use Disorders
2024, Biological Psychiatry
Substance use disorders are a set of recalcitrant neuropsychiatric conditions that cause tremendous morbidity and mortality and are among the leading causes of loss of disability-adjusted life years worldwide. While each specific substance use disorder is driven by problematic use of a different substance, they all share a similar pattern of escalating and out-of-control substance use, continued use despite negative consequences, and a remitting/relapsing pattern over time. Despite significant advances in our understanding of the neurobiology of these conditions, current treatment options remain few and are ineffective for too many individuals. In recent years, there has been a rapidly growing body of literature demonstrating that the resident population of microbes in the gastrointestinal tract, collectively called the gut microbiome, plays an important role in modulating brain and behavior in preclinical and clinical studies of psychiatric disease. While these findings have not yet been translated into clinical practice, this remains an important and exciting avenue for translational research. In this review, we highlight the current state of microbiome-brain research within the substance use field with a focus on both clinical and preclinical studies. We also discuss potential neurobiological mechanisms underlying microbiome effects on models of substance use disorder and propose future directions to bring these findings from bench to bedside.
Cardiovascular changes under the microgravity environment and the gut microbiome
2024, Life Sciences in Space Research
In view of the critical role the gut microbiome plays in human health, it has become clear that astronauts' gut microbiota composition changes after spending time in space. Astronauts are exposed to several risks in space, including a protracted period of microgravity, radiation, and mechanical unloading of the body. Several deleterious effects of such an environment are reported, including orthostatic intolerance, cardiovascular endothelial dysfunction, cellular and molecular changes, and changes in the composition of the gut microbiome. Herein, the correlation between the gut microbiome and cardiovascular disease in a microgravity environment is evaluated. Additionally, the relationship between orthostatic hypotension, cardiac shrinkage and arrhythmias during spaceflight, and cellular alterations during spaceflight is reviewed. Given its impact on human health in general, modifying the gut microbiota may significantly promote astronaut health and performance. This is merited, given the prospect of augmented human activities in future space missions.

View all citing articles on Scopus

: Conflict of interest Fergus Shanahan is a co-founder of Alimentary Health Ltd. and Atlantia Food Clinical Trials, and with Paul W. O’Toole is co-founder of Tucana Health (now 4D pharma Cork). Tarini S. Ghosh declares no conflict of interest.

: Funding This research is supported, in part, by Science Foundation Ireland (grant number SFI/12/RC/2273).

View full text

ArticleThe Healthy Microbiome—What Is the Definition of a Healthy Gut Microbiome?

Graphical abstract

Section snippets

Dear Doctor

What’s in a Word?

Classifying Microbiomes

Functional Redundancy

Lessons From Outliers

Strains Matter

The Changing Nature of the Microbiome and Its Clinical Implications

Beyond Bacteria

Future Directions

Acknowledgments

Cell

Mucosal Immunol

J Nutr

Cell

Lancet

Curr Opin Microbiol

Cell

Cell Host Microbe

Cell Host Microbe

Cell

Trends Endocrinol Metab

Am J Clin Nutr

Gastroenterology

Cell Host Microbe

The unseen world: reflections on Leeuwenhoek (1677) ‘Concerning little animals

Phil Trans R Soc B

Human and Helicobacter pylori coevolution shapes the risk of gastric disease

Proc Natl Acad Sci U S A

The role of CagA in the gastric biology of Helicobacter pylori

Cancer Res

Disappearing microbiota: Helicobacter pylori protection against esophageal adenocarcinoma

Cancer Prev Res (Phila)

The oral microbiota in colorectal cancer is distinctive and predictive

Gut

Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer

Nat Med

The gut microbiota in causation, detection, and treatment of cancer

Am J Gastroenterol

A Bifidobacterial pilus-associated protein promotes colonic epithelial proliferation

Mol Microbiol

Gut microbes: from bugs to drugs

Am J Gastroenterol

A clinician's guide to microbiome analysis

Nat Rev Gastroenterol Hepatol

Towards standards for human fecal sample processing in metagenomic studies

Nat Biotechnol

The meaning of health scares

Through the looking-glass. chapter 6

Language, numeracy and logic in microbiome science

Nat Rev Gastroenterol Hepatol

Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications

Cell Host Microbe

The healthy human microbiome

Genome Med

The hunt for a healthy microbiome

Nature

In the era of precision medicine and big data, who is normal?

JAMA

American gut: an open platform for citizen science microbiome research

mSystems

Population-level analysis of gut microbiome variation

Science

Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity

Science

Ranking microbiome variance in inflammatory bowel disease: a large longitudinal intercontinental study [published online ahead of print June 14, 2020]

Gut

Environment dominates over host genetics in shaping human gut microbiota

Nature

Depicting the composition of gut microbiota in a population with varied ethnic origins but shared geography

Nat Med

Regional variation limits applications of healthy gut microbiome reference ranges and disease models

Nat Med

Article
The Healthy Microbiome—What Is the Definition of a Healthy Gut Microbiome?